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We related the ability of eleven pyridinium and imidazolium aldoximes to reactivate tabun-in-
hibited human erythrocyte acetylcholinesterase with their molecular properties. Using molecu-
lar mechanics we performed conformational analysis to determine the flexibility of the ald-
oximes. Semi-empirical calculations show that differences in reactivation rates probably do not
origin from different electron density on the oxygen of the oxime group, but can be explained
by the steric hindrance within the aldoxime molecule. Tabun-inhibited acetylcholinesterase
was efficiently reactivated by flexible bispyridinium para-aldoximes with propylene or buty-
lene linker. Although pyridinium/imidazolium aldoximes with the oxime group in ortho-posi-
tion did not show significant reactivation ability, they protected acetylcholinesterase against
phosphorylation by tabun due to their high affinity for the native acetylcholinesterase. The ald-
oximes were examined for cytotoxicity on different cell lines and no cytotoxic effect was ob-














The availability of highly toxic organophosphorus com-
pounds (OP), such as nerve agents, underlines the neces-
sity for an effective medical treatment. Acute OP toxici-
ty is primarily caused by the inhibition of acetylcholin-
esterase (AChE; EC 3.1.1.7) via phosphorylation of the
enzyme catalytic site.1 Reactivators of inhibited AChE,
such as aldoximes, are a mainstay of the treatment.2
However, the commercially available aldoxime, 2-PAM,
is considered to be rather ineffective against various ner-
ve agents, e.g. tabun.3 This led to the synthesis and in-
vestigation of numerous aldoximes in the past deca-
des.2,4–6 TMB-4 is one of the classical aldoximes and an
effective reactivator of AChE phosphorylated by ta-
bun.3,6 Our recent reactivation studies with pyridinium
aldoximes, which are similar to TMB-4 with the para-
positioned oxime group, gave promising results in reac-
tivating tabun-phosphorylated AChE and in the therapy
of tabun-poisoning in mice.7,8
In this paper we bring together our previous results
and the results of our in vitro study on aldoximes, shown
in Figure 1, with the aim to relate the molecular proper-
ties of each aldoxime to its reactivation potency. To this
end, we performed the conformational analysis of the al-
doximes and determined the reactivation rate constants
of human erythrocyte AChE inhibited by tabun. We also
determined aldoxime protective potency against AChE
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inhibition by tabun because in addition to acting as reac-
tivators, aldoximes are also reversible inhibitors of
AChE, and they protect the enzyme catalytic site against
phosphorylation due to direct competition between them
and the phosphorylating agent for binding to the enzy-
me’s active site.9,10 When we obtained promising results,
we tested the cytotoxicity of the aldoximes on a defined
set of cell lines. This kind of screening in the early stage
of antidote development is a very important tool that can
point out possible toxic effects of what appears as a
promising compound, and can lead to structural optimi-
sation of an aldoxime.
EXPERIMENTAL
Chemicals
Aldoxime structures are given in Figure 1. HI-6 [1-(((4-car-
bamoylpyridinium-1-yl)methoxy)methyl)-2-((hydroxyimino)-
methyl)pyridinium chloride] was synthesized in the Depart-
ment of Organic Chemistry, Faculty of Science, University
of Zagreb, Croatia. TMB-4 [N,N'-(propano)bis(4-hydroxy-
iminomethyl)pyridinium bromide] was obtained from Bo-
snalijek, Sarajevo, Bosnia and Herzegovina. DMB-4 [N,N'-
(ethano)bis(4-hydroxyiminomethyl)pyridinium methanosul-
phonate], MMB-4 [N,N'-(methano)bis(4-hydroxyiminome-




no)methyl)pyridinium chloride], ICD-692 [4-carbamoyl-1-
(3-(2-((hydroxyimino)methyl)-1-methyl-1H-imidazol-3-ium-3-
yl)propyl)pyridinium chloride] and ICD-467 [2-((hydroxy-
imino)methyl)-1-methyl-3-((3-methyl-3-nitrobutan-2-yloxy)me-
thyl)-1H-imidazol-3-ium chloride] were obtained from US
Army Medical Research Institute of Chemical Defense,
Aberdeen Proving Ground, MD, USA. K033 [1,4-bis(2-hy-
droxyiminomethylpyridinium) butane dibromide], K027
[1-1(4-hydroxyiminomethylpyridinium)-3-(4-carbamoylpyri-
dinium) propane dibromide] and K048 [1-(4-hydroxyimi-
nomethylpyridinium)-4-(4-carbamoylpyridinium) butane di-
bromide] were provided by Kamil Ku~a, Faculty of Mili-
tary Health Sciences, Hradec Kralove, Czech Republic. Ta-
bun [ethyl N,N-dimethylphosphoroamididocyanidate] was
purchased from NC Laboratory, Spiez, Switzerland. Acetyl-
thiocholine iodide (ATCh) and 5,5'-dithiobis(2-nitrobenzoic
acid) (DTNB) were purchased from Sigma Chemical Co.,
St. Louis, MO, USA.
Conformational Analysis of the Aldoximes
Conformational analysis was performed using MM2 and
semi-empirical calculations with MOPAC 2000 software
(PM-3 method with COSMO solvation model) created by J.
J. P. Stewart (Fujitsu Ltd., Tokyo, Japan, 1999) according to
published procedures.11,12
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Figure 1. Structure of the aldoximes used in the study.
AChE Activity Measurement
Native non-haemolysed human erythrocytes were the sour-
ce of AChE; the final dilution during the enzyme assay was
400-fold. All experiments were done in 0.1 mol dm–3 so-
dium phosphate buffer, pH = 7.4, at 25 °C. The enzyme ac-
tivity was measured spectrophotometrically according to
the Ellman procedure13 with the thiol reagent DTNB (0.3
mmol dm–3 final concentration) and ATCh as substrate. The
increase in absorbance was read at 436 nm up to 2 min. All
spectrophotometric measurements were performed on a
CARY 300 spectrophotometer (Varian Inc., Australia).
Reactivation of Tabun-inhibited AChE
Undiluted erythrocytes were incubated with 5 mmol dm–3
tabun up to 60 min achieving 90–100 % inhibition. The in-
cubation mixture was diluted 10 times with 0.1 mol dm–3
phosphate buffer, pH = 7.4, containing the aldoxime to start
reactivation. After a given time of reactivation aliquots
were diluted 40 times, DTNB and ATCh (1.0 mmol dm–3
final concentration) were added, and the enzyme activity
was measured. An equivalent sample of uninhibited enzy-
me was diluted to the same extent as the inhibited AChE,
and control activity was measured in the presence of ald-
oxime at concentrations used for reactivation. Both activi-
ties of control and reactivation mixture were corrected for
oxime-induced hydrolysis of ATCh. No spontaneous reacti-
vation of the phosphorylated enzyme took place.
Oxime-assisted reactivation of phosphorylated AChE
proceeds according to Scheme 1:
where EP is the phosphorylated enzyme, [EP][OX] is the
reversible Michaelis-type complex between EP and the
aldoxime (OX), E is the active enzyme and P-OX the
phosphorylated aldoxime, k+2 is the maximum first-order
rate constant, and kr is the overall second-order rate con-


















where [EP]0 and [EP]t are concentrations of phosphorylated
enzyme at time zero and at time t, respectively. KOX is
equal to the ratio (k–1 + k+2)/k+1, and it approximates the
dissociation constant of the [EP][OX] complex. kobs is the
observed first-order rate constant of reactivation at a given
aldoxime concentration. The overall second-order rate con-






















t( )EP OX+ is activity of reactivated enzyme at time t
and v( )E OX+ stands for activity of enzyme incubated with
aldoxime. Since (100 – Reactivation) / % is equal to
100⋅[EP]t / [EP]0, one can relate the experimental data to
Eq. (1). At each aldoxime concentration, kobs was calcula-
ted from the slope of the initial portion of log [(100 – Reac-
tivation) / %)] vs. time of reactivation. Reactivation with
each aldoxime followed Eq. (1). Therefore, k+2 and KOX
were obtained by the non-linear fit of the relationship be-
tween kobs vs. [OX], while kr was calculated using Eq. (2).
Reversible Inhibition of AChE
Reversible inhibition of AChE by aldoximes was measured
in a medium which contained erythrocytes suspended in
buffer, DTNB, the aldoxime and ATCh.
The inhibition constants were evaluated from the effect
of substrate concentration on the degree of inhibition ac-
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Kapp is the apparent enzyme-aldoxime dissociation
constant at a given substrate concentration [S], calculated
from the enzyme activities v0 and v measured in the absen-
ce and in the presence of the aldoxime (OX), respectively.
Ki is the enzyme-aldoxime dissociation constant of a com-
plex formed in the catalytic site. Ks is the enzyme-substrate
dissociation constant which should correspond to the Mi-
chaelis constant, if aldoxime binds only to the catalytic site.
Protection of AChE against Phosphorylation
Protection of AChE against phosphorylation by tabun was
measured in a medium which contained erythrocytes sus-
pended in 0.1 mol dm–3 phosphate buffer, DTNB, aldoxi-
me, and tabun (100 nmol dm–3). After a given time of phos-
phorylation (up to 5 min) ATCh (1.0 mmol dm–3 final con-
centration) was added and the increase in absorbance was
read for 1 min. Control samples contained no aldoxime.
The second-order rate constant of inhibition by ta-







i OP= ⋅ ⋅[ ] t (5)
where vOP and v0 are enzyme activities with and without
tabun, respectively; [OP] is the concentration of tabun, and
t is the time of inhibition. Protection was expressed in terms







The second-order rate constant of inhibition in the
presence of aldoxime (k'i) was calculated using Eq. (5)
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Scheme 1.
where v0 and vOP denote enzyme activities in the absence of
both aldoxime and tabun, and in their presence, respec-
tively.
Protective indexes for all tested aldoximes were also
determined theoretically from:
PItheor = 1 + [OX]/Ki (7)
where [OX] stands for aldoxime concentration, and Ki is
the experimentally determined enzyme-aldoxime dissocia-
tion constant.
Oxime-catalysed Hydrolysis of Acetylthiocholine
The reaction of ATCh with aldoxime was measured for 1
min in a medium which contained ATCh, aldoxime, DTNB
and 0.1 mol dm–3 phosphate buffer, pH = 7.4 at 25 °C. Two
to four measurements were done with each ATCh/aldoxime
concentration pair. The second-order rate constant of the
non-enzymatic reaction (kNE) was calculated according to
the following equation:
c / t = kNE ⋅ [S]⋅[OX] (8)
where c is the released thiocholine concentration, t is the ti-
me of reaction, and [S] and [OX] are the initial ATCh and
aldoxime concentrations, respectively. Thiocholine concen-
tration was calculated from the absorbance monitored at
436 nm (eM = 11 000 dm3 mol–1 cm–1).14
Cell Lines
Three malignant cell lines: human monocytic leukemia
(THP-1, monocyte, ECACC-88081201),15 human Cauca-
sian hepatocyte carcinoma (Hep G2, epithelial, ECACC-
85011430)16 and Chinese Hamster Ovary cells (CHO, epi-
thelial, ECACC-85050302)17 were obtained from the Euro-
pean Collection of Cell Cultures, Great Britain. Human
whole white blood cells (hWBC), isolated human polimor-
phonuclear cells (hPMN) and human peripheral blood mo-
nonuclear cells (hPMB) were prepared in GlaxoSmithKline
Research Centre Zagreb Ltd., Croatia. Blood was obtained
from the Transfusion Centre Zagreb, Croatia. All cells were
maintained in completed RPMI 1640 medium (Institute of
Immunology, Zagreb, Croatia) supplemented with 10 %
Foetal Bovine Serum (BioWest, Nuille, France) at 37 °C in
5 % CO2 atmosphere. Cells were passaged twice a week to
be kept in a rapid-growth phase.
Cytotoxicity Assay
Cells in the rapid-growth phase were exposed to the ald-
oximes. MTS reagent [3-(4,5-dimethylthiazole-2-yl)-2,5-di-
phenyl tetrazolium bromide] was used to measure the suc-
cinate dehydrogenase mitochondrial activity of living cells.
This enzyme cuts the tetrazolium ring of MTS giving for-
mazan that was determined spectrophotometrically at 490
nm.18 Formazan develops only in the living and early apo-
ptotic cells.
The aldoximes were examined for antiproliferative or
cytotoxic effects following continuous exposure using the
CellTiter 96® AQueous One Solution Cell Proliferation As-
say (MTS Assay, Promega, USA). All aldoximes were pre-
pared in DMSO as 10–2 mol dm–3 solutions, and added to
the microtiter plate wells in the final concentrations of 800,
400, 200, 100, 50, 25, 12.5 and 6.25 mmol dm–3. Final dilu-
tion of DMSO did not exceed 1 %. The assay was perfor-
med on a defined set of different cell lines and each well
contained 50 000 cells or 75 000 in the case of THP-1 cells.
After cells were exposed to the aldoximes or 10 % DMSO
as control for 24 h, 15 mL of MTS reagent (Promega, USA)
was added to the cells cultured in microtiter plates. Absor-
bance was recorded with a spectrophotometric plate reader
(Ultra, TECAN, USA). The method was programmed for
TECAN robotic system in GEMINI pipetting software.19
The results were expressed as OD values of non-treated
cells and as IC50 values.
RESULTS AND DISCUSSION
Proper orientation in the active site gorge with the oxime
group positioned towards the phosphorylated catalytic
serine is one of the most important requirements for ald-
oximes that are being tested as reactivators of inhibited
AChE.20,21 Since the overall flexibility of the aldoxime
molecule is a key property for achieving stabilisation in
the vicinity of phosphorylated active site,22 we per-
formed the conformational analysis of the aldoximes
(Figure 1) in order to relate their molecular properties to
the studied AChE interactions. Table I shows the energy
of aldoxime rotation bonds, while minimised aldoxime
structures and the spatial arrangement of the oxime
groups bonded to the pyridinium or imidazolium ring is
presented in Figure 2. Generally, aldoximes with the oxi-
me group in the ortho-position (ICD-585, HI-6, K033,
ICD-692 and ICD-467) were less flexible than those with
the oxime group in the para-position (K027, K048,
TMB-4, DMB-4 and MMB-4) due to a higher rotation
barrier of the N(3)–C(13) or N(1)–C(2) bond.23,24 A
higher rotation barrier in the ortho-aldoximes was cau-
sed by the steric hindrance of the linker connecting two
rings, or in the case of ICD-467 the ring with the bulky
aliphatic group. Although in MMB-4 oxime groups are
para-positioned, the rotation barrier was higher than in
other para-aldoximes due to a short linker.24 Pyridinium
rings of MMB-4 are stabilised in conformation with the
angle of about 90° (Figure 2), and for their rotation addi-
tional energy is required. The rotation of a pyridinium
ring carrying both ortho- and para-oxime groups, like in
HLö-7, needs the same energy as in aldoximes with the
ortho-positioned oxime group. Interestingly, the energy
for the rotation of the oxime group (bond C(6)/C(2)–
C(19)/C(20)) is the same regardless of its ortho- or
para-position at the pyridinium ring, but is higher if the
oxime group is ortho-positioned at the imidazolium ring.
50 Z. KOVARIK et al.
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(a) Energies were calculated using the MM2 method. (b)Asterisk denotes averaged value due to symmetry in the molecule.
TABLE II. Reactivation of tabun-inhibited human erythrocyte acetylcholinesterase by tested aldoximes(a),(b),(c)









ICD-585 (0.1−1.0) ND ND ND <15 24 h this paper
HI-6 (0.1−1.0) ND ND ND 10 24 h 7
HLö-7 (0.03−1) 0.008 ± 0.0005 0.047 ± 0.014 170 ± 51.8 80 8 h this paper
K027 (0.03−5.0) 0.032 ± 0.002 0.085 ± 0.020 376 ± 92 100 2 h 7
K048 (0.05−5.0) 0.074 ± 0.003 0.11 ± 0.01 673 ± 67 100 30 min 7
K033 (0.1−1.0) 0.002 ± 0.0003 0.20 ± 0.10 10 ± 5 60 24 h 7
TMB-4 (0.05−10.0) 0.15 ± 0.02 0.49 ± 0.20 306 ± 131 100 20 min 7
DMB-4 (0.1−3.0) 0.002 ± 0.0001 0.048 ± 0.015 41.7 ± 13.2 70 16 h 24
MMB-4 (0.1−3.0) 0.004 ± 0.0004 0.28 ± 0.10 14.3 ± 5.3 80 10 h 24
ICD-692 (0.1−1.0) ND ND ND <15 24 h this paper
ICD-467 (0.1−1.0) ND ND ND <15 24 h this paper
(a) Constants (± standard errors) are calculated by Eqs. (1)–(3) from kobs constants obtained in at least three experiments.
(b)Maximum reactivation
(Reactmax) measured within the specified time of the experiment is also given.
(c)ND = not determined.
The highest rotation energy barriers observed for the
bonds in the linker determined the overall aldoxime ri-
gidness. Therefore, the most rigid aldoxime appeared to
be the imidazolium aldoxime ICD-467 having the bulky
3-methyl-3-nitrobutane-2-yl group. Semi-empirical cal-
culations also showed that the aldoximes had similar
electron density for protonated oxygen (–0.35) and for
deprotonated oxygen (–0.89) in the oxime group.
Table II shows the kinetic parameters for the reacti-
vation of tabun-inhibited human AChE by the aldoxi-
mes, and one representative experiment is shown in Fig-
ure 3. Of all tested aldoximes two para-aldoximes,
K048 and K027 had the highest reactivation potency for
tabun-inhibited AChE because their relatively low con-
centrations were able to completely reactivate AChE in
a short time.7 Because of a fast first-order reactivation
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TABLE III. Reversible inhibition of human erythrocyte acetylcholinesterase by tested aldoximes(a)
Aldoxime ([OX]/mmol dm–3) [ATCh] / mmol dm–3 Ki ± SE / mmol dm
–3 Ks ± SE / mmol dm
–3 Reference
ICD-585 (0.010–0.080) 0.1–1.0 0.028 ± 0.002 0.88 ± 0.12 this paper
HI-6 (0.05–0.4) 0.1–5.0 0.031 – 35
HLö-7 (0.010–0.080) 0.1–1.0 0.024 ± 0.004 0.77 ± 0.18 this paper
K027 (0.064–0.45) 0.05–0.3 0.073 ± 0.01 0.13 ± 0.02 7
K048 (0.1–0.5) 0.05–1.0 0.11 ± 0.01 0.47 ± 0.08 7
K033 (0.01–0.2) 0.05–1.0 0.017 ± 0.002 0.79 ± 0.22 7
TMB-4 (0.1–0.7) 0.05–0.7 0.18 ± 0.01 0.96 ± 0.16 7
DMB-4 (0.05–0.50) 0.1–1.0 0.10 ± 0.02 0.74 ± 0.19 24
MMB-4 (0.25–0.70) 0.1–1.0 0.49 ± 0.07 0.48 ± 0.09 24
ICD-692 (0.010–0.040) 0.1–1.0 0.018 ± 0.001 7.8 ± 16 this paper
ICD-467 (0.005–0.010) 0.1–1.0 0.0012 ± 0.0001 1.4 ± 0.4 this paper
(a) Dissociation constants (± standard errors) were calculated using Eq. (4) from Kapp obtained in at least three experiments.
Figure 2. Minimised structures of the studied aldoximes. Presented atoms are carbon (dark grey), nitrogen (blue), oxygen (red). Hydrogen
atoms are not shown for better visibility.
rate, TMB-4 also showed a significant reactivation po-
tential.24 Reactivation assisted by ortho-aldoximes was
observed only with bispyridinium K033, reaching 60 %
after 24 h. Maximum reactivation by other ortho-pyri-
dinium aldoximes, ICD-585 and HI-6, and ortho-imida-
zolium aldoximes, ICD-692 and ICD-467, was lower
than 15 %, and therefore their reactivation constants
could not be determined. With HLö-7, a pyridinium ald-
oxime with both ortho- and para-positioned oxime
groups on the pyridinium ring, enzyme activity was al-
most completely restored; primarily due to its high affin-
ity for phosphorylated AChE (lower KOX; Table II).
These results confirmed earlier studies with HLö-7.25,26
However, except for K027, K048 and TMB-4 no aldoxime
showed complete reactivation, and the kinetics at the
longer time intervals deviated from the first-order pro-
cess described in Eq. (1). This deviation could be due to
the post-inhibitory dealkylation of the phosphorylated
enzyme known as aging.26 It is known that the aging of
tabun-inhibited human AChE is slow with the half-life
of 13 h.27 The other reason could be re-inhibition of the
active enzyme by the phosphorylated aldoxime,21,28 but
no data on the inhibitory potency of conjugates of tabun
and studied aldoximes is available in literature. How-
ever, conjugates of tabun and monopyridinium para-ald-
oxime 4-PAM or ortho-aldoxime 2-PAM were poor in-
hibitors of AChE, which was attributed to a combination
of steric factors and a reduction in the electro-positivity
of the phosphorus atom.29 Therefore, aldoxime structure
seemed to be the critical factor for tabun reactivation. It
appears that, to reactivate tabun-inhibited AChE effi-
ciently, the oxime group needs to be in the para-position
on the pyridinium ring and the length of the linker be-
tween two rings should be three or four CH2 groups. The
type of the linker (propylene or oxapropylene) is less
important. However, potent reactivators were also buty-
lene-linked bisoximes that instead of pyridinium had
imidazolium rings and the oxime group in the ortho-po-
sition.30 Indeed, bispyridinium para-aldoximes with
shorter linker than propylene and longer than butylene
or monopyridinium para-aldoximes were not effective
tabun-phosphorylated AChE reactivators.26,31,32 A reac-
tivation study of diisopropylphosphoryl-AChE showed
that the most promising bispyridinium para-aldoxime
was a propylene-linked bisaldoxime, while the most pro-
mising bispyridinium ortho-aldoxime was a heptylene-
linked bisaldoxime.33 The crystal structure of aldoxime-
AChE complex explains different requirements of the
chain length for reactivation; the most potent reacti-
vators should span the active site of the phosphorylated
AChE, and pyridinium rings should be stabilised by aro-
matic residues in the peripheral site and choline binding
site of AChE.34
Since aldoximes are also reversible inhibitors of
AChE, we determined dissociation constants of aldoxi-
me-human erythrocyte AChE complex using Eq. (4)
(Table III). The catalytic site of AChE showed the high-
est affinity (the lowest Ki) for ICD-467, at least twenty
times higher than that for the other aldoximes. The de-
termined Ki constants were similar to constants publi-
shed for other bispyridinium compounds.35 However,
the binding affinity of the aldoximes to the free enzyme
mostly did not correlate with aldoxime efficacy in enzy-
me reactivation (cf. Table II). Therefore, if an aldoxime
with a high binding affinity is stabilised far from the
phosphorus atom, this aldoxime has a limited reactiva-
tion potency, which means that reactivation primarily
depends on the displacement rate of the phosphorus
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Figure 3. Reactivation of tabun-inhibited human erythrocyte AChE
by HLö-7. (a) A single data point indicates calculated reactivation
using Eq. (3). (b) Slopes of the reactivation curve yield kobs con-
stants. (c) kobs is plotted as a function of HLö-7 and the curve is
fitted using Eq. (1).
moiety.36 The Ks values, derived from the kinetics of in-
hibition with aldoximes were higher, but close to the
previously determined KM.37 This supports our belief
that the determined Ki constants correspond to the bind-
ing to the catalytic site of AChE. A higher Ks as well as
its standard error for ICD-692 is probably due to an in-
dependence of Kapp from substrate concentration, which
implies binding to the active site, but not to the catalytic
site. However, higher substrate concentrations could not
be used to determine possible aldoxime binding to the
peripheral site of AChE because aldoximes reacted with
acetylthiocholine and interfered with the enzyme as-
say.38–40 The rate constants for aldoxime-catalysed hy-
drolysis of acetylthiocholine are given in Table IV. The
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Figure 4. Progressive inhibition of AChE by tabun in the
absence and in the presence of ICD-585, ICD-692,
Hlö-7 (20 mmol dm–3) and ICD-467 (2 mmol dm–3)
wherefrom protective indexes were determined. Slopes
represent the first-order inhibition rate constants.
TABLE IV. Non-enzymatic reaction between the substrate acetylthiocholine (ATCh) and the aldoximes(a)
Aldoxime [OX]/mmol dm–3 [ATCh] / mmol dm–3 kNE / dm
3 mol–1 min–1 Reference
ICD-585 0.01−0.08 0.1−1.0 14.2 ± 0.4 this paper
HI-6 0.025−0.6 0.05−1.0 10.7 ± 0.1 this paper
HLö-7 0.0025−0.08 0.1−1.0 32.1 ± 0.9 this paper
K027 0.06−3.2 0.05−1.0 12.0 ± 0.4 this paper
K048 0.1−3.0 0.05−1.0 15.5 ± 0.4 this paper
K033 0.01−0.3 0.05−1.0 25.6 ± 0.9 this paper
TMB-4 0.1−0.7 0.05−1.0 31.0 ± 0.5 24
DMB-4 0.05−0.5 0.1−1.0 29.3 ± 1.0 24
MMB-4 0.25−0.7 0.1−1.0 32.0 ± 1.0 24
ICD-692 0.01−0.05 0.1−1.0 13.7 ± 0.4 this paper
ICD-467 0.005−0.20 0.1−1.0 17.2 ± 0.7 this paper
(a)Constants (± standard errors) were calculated in given concentration ranges using Eq. (8).
oxime group reacts with the AChE substrate acetylthio-
choline on a 1:1 mole ratio basis, and thiocholine is one
of the reaction products.23,41 Therefore the rate of bis-
oximes is double that of monoximes. Constants were si-
milar to the rate constant obtained for LüH6 (obidoxi-
me), a bispyridinium aldoxime.35
As reversible inhibitors, aldoximes protect the cata-
lytic serine against phosphorylation, which means that
even though oxime-mediated reactivation is poor, ald-
oximes could be used as prophylactic agents.8,42 We mea-
sured progressive inhibition of AChE by tabun in the ab-
sence and in the presence of aldoximes (Figure 4), and
calculated protective indexes (PI; Table V). All tested
aldoximes in concentrations corresponding to their Ki
protected the enzyme from phosphorylation by tabun. A
limited protection ability shown by ICD-692 and
MMB-4 could be explained with lower concentrations
used than their Ki. The lower concentration for MMB-4
was intentional, because of its high Ki, but for ICD-692
it implies a deviation from the determined Ki as discus-
sed in paragraph above. The protective index was also
evaluated theoretically for all tested aldoximes. The
relationship between experimentally and theoretically
obtained protective indexes could be used to determine
the aldoxime binding site in AChE.42 Since experimen-
tally determined PI corresponded to the theoretically ob-
tained PItheor using Eq. (7) (except for ICD-692), the
aldoximes protected the enzyme primarily by binding to
the catalytic site. As already mentioned, an additional
study should provide a detailed mapping of the ICD-692
binding site in AChE.
Cytotoxicity screening was used to establish the ba-
sic cytotoxicity of the tested aldoximes. We used differ-
ent cell lines, THP-1, Hep G2, CHO, as well as human
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Figure 5. Cytotoxicity of the studied oximes on cell lines and human blood cells.
white blood cell types hWBC, hPMN and hPBM. The
cytotoxic effect of tested aldoximes in 8 concentrations
up to 0.8 mmol dm–3 was evaluated by measuring the
activity of mitochondrial succinate dehydrogenase of the
living cells. Figure 5 shows dose-response curves ex-
pressed as the OD values of non-treated cells. Only
HLö-7 showed a weak growth inhibition in most cell
types, with the IC50 ranging between 0.4 and 0.8 mmol
dm–3. Since concentrations higher than 0.1 mmol dm–3
are not suitable for human use,43 observed citotoxicity of
HLö-7 does not limit further investigation of HLö-7. In-
terestingly, a stimulation of human polimorphonuclear
cells was observed with MMB-4 after 24 hours, with the
effect similar to the treatment of cells with 10 % DMSO.
We did not observe a dose-response viability curve for
other aldoximes for all cell types tested, which suggests
that the aldoximes showed no cytotoxic effect in concen-
trations up to 0.8 mmol dm–3 (IC50 > 0.8 mmol dm–3).
These results are in agreement with a previous cytotoxi-
city study on the same cell lines showing no cytotoxic
effect of TMB-4, HI-6, K027, K033 and K048.7
CONCLUSIONS
Pyridinium aldoximes with the oxime group in the para-
position at the pyridinium ring were more flexible than
those with the oxime group in the ortho-position at the
pyridinium ring due to the lower rotation barrier of the
N(3)–C(13) bond. All pyridinium aldoximes had the high-
est rotation barrier of the linker bonds 30 kcal mol–1.
The most rigid aldoxime was the imidazolium aldoxime
ICD-467, due to steric hindrance caused by the bulky
3-methyl-3-nitrobutane-2-yl group.
All bispyridinium aldoximes with the oxime group
in the para-position were efficient reactivators of ta-
bun-inhibited AChE; the most potent reactivator was
K048, followed by K027, TMB-4, HLö-7, DMB-4 and
MMB-4. Five compounds with the oxime group in the
ortho-position did not show significant reactivation po-
tency for tabun-inhibited AChE.
All the aldoximes reversibly inhibited AChE and
protected AChE against phosphorylation with tabun.
The most potent inhibitors were the aldoximes with the
oxime group in the ortho-position which did not show
significant reactivation ability. Therefore, these oximes
might be of interest as pre-treatment drugs due to their
high affinity for the native AChE.
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SA@ETAK
In vitro reakcije aldoksima i ljudske acetilkolinesteraze
Zrinka Kovarik, Maja ^ali}, Anita Bosak, Goran [inko i Dubravko Jeli}
Prou~avali smo reaktivaciju ljudske eritrocitne acetilkolinesteraze inhibirane tabunom, pri ~emu smo po-
vezali molekulske karakteristike jedanaest aldoksima s njihovim brzinama reaktivacije. Proveli smo konfor-
macijsku analizu aldoksima primjenom molekulske mehanike kako bismo odredili savitljivost pojedinih aldok-
sima. Semiempirijski prora~uni su pokazali da razlike u brzinama reaktivacije nisu posljedica razli~ite elek-
tronske gusto}e na atomu kisika oksimske skupine, ve} mogu biti obja{njene steri~kim smetnjama unutar same
molekule. U~inkovita reaktivacija inhibirane acetilkolinesteraze postignuta je sa savitljivijim bispiridinijevim
para-aldoksimima koji imaju propilensku ili butilensku poveznicu. Iako piridinijevi ili imidazolijevi aldoksimi
s oksimskom skupinom u ortho-polo`aju nisu u~inkovito reaktivirali fosforiliranu acetilkolinesterazu, oni su je
{titili od fosforilacije tabunom zbog njihovog visokog afiniteta vezanja za nativnu acetilkolinesterazu. Ispitana
je i citotoksi~nost aldoksima za razli~ite stani~ne linije. Citotoksi~ni efekt aldoksima nije primije}en do njihove
koncentracije od 400 mmol dm–3.
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